Neurocrine begins Phase I trial of NBIP-‘1968 triple agonist for obesity
Executive Overview In a significant milestone for metabolic therapeutics, biopharmaceutical innovator Neurocrine Biosciences has officially commenced a Phase I clinical trial evaluating NBIP-’1968. This novel, investigational long-acting triple agonist is…